DDInter125 DDInter224
Developed by Schering-Plough after its merger with Organon International, asenapine is a sublingually administered, atypical antipsychotic for treatment of schizophrenia and acute mania associated with bipolar disorder. Asenapine also belongs to the dibenzo-oxepino pyrrole class. It is also for severe post-traumatic stress disorder nightmares in soldiers as an off-label use. FDA approved on August 13, 2009.
Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q11), resulting in a BCR-ABL fusion protein.[A6902,A261796,A261801] The first BCR-ABL inhibitor, [imatinib], was introduced over a decade ago as a breakthrough in CML management; however, emerging resistance to [imatinib] poses challenges in achieving remission. Second-generation BCR-ABL inhibitors like bosutinib inhibit most resistance-conferring BCR-ABL mutations except V299L and T315, thus providing more therapeutic options for patients.[A6901,A17961] Bosutinib was first approved by the FDA in 2012 for the treatment of adult chronic, accelerated, or blast-phase Ph+ CML with resistance or intolerance to prior therapy. On September 26, 2023, bosutinib was also approved by the FDA for the treatment of pediatric CML that is newly diagnosed or resistant/intolerant to prior therapy. This approval was based on favorable results obtained from the open-label, randomized, multicenter trial BFORE that showed a significant improvement in major molecular response, defined as a ≤0.1% BCR ABL ratio on an international scale, with bosutinib treatment.
Asenapine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Bosutinib
Asenapine {u} (Compound) causes {v} (Side Effect) Cardiac disorder
Cardiac disorder {u} (Side Effect) is caused by {v} (Compound) Bosutinib
Asenapine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Gefitinib
Gefitinib {u} (Compound) resembles {v} (Compound) Bosutinib
Asenapine {u} (Compound) causes {v} (Side Effect) Cardiac disorder
Cardiac disorder {u} (Side Effect) is caused by {v} (Compound) Gefitinib
Gefitinib {u} (Compound) resembles {v} (Compound) Bosutinib
Asenapine {u} (Compound) causes {v} (Side Effect) Arthralgia
Arthralgia {u} (Side Effect) is caused by {v} (Compound) Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bosutinib
Asenapine {u} (Compound) resembles {v} (Compound) Loxapine
Loxapine {u} (Compound) resembles {v} (Compound) Clozapine
Clozapine {u} may lead to a major life threatening interaction when taken with {v} Bosutinib
Asenapine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) covaries with {v} (Gene) PTK2B
PTK2B {u} (Gene) is bound by {v} (Compound) Bosutinib
Asenapine {u} (Compound) causes {v} (Side Effect) Electrocardiogram QT prolonged
Electrocardiogram QT prolonged {u} (Side Effect) is caused by {v} (Compound) Famotidine
Famotidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bosutinib
Asenapine {u} (Compound) causes {v} (Side Effect) Alanine aminotransferase increased
Alanine aminotransferase increased {u} (Side Effect) is caused by {v} (Compound) Rilpivirine
Rilpivirine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bosutinib
Asenapine {u} (Compound) resembles {v} (Compound) Amoxapine
Amoxapine {u} (Compound) resembles {v} (Compound) Quetiapine
Quetiapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bosutinib
Asenapine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bosutinib (Compound)
Asenapine (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Bosutinib (Compound)
Asenapine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Gefitinib (Compound) and Gefitinib (Compound) resembles Bosutinib (Compound)
Asenapine (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Gefitinib (Compound) and Gefitinib (Compound) resembles Bosutinib (Compound)
Asenapine (Compound) causes Arthralgia (Side Effect) and Arthralgia (Side Effect) is caused by Metronidazole (Compound) and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Bosutinib
Asenapine (Compound) resembles Loxapine (Compound) and Loxapine (Compound) resembles Clozapine (Compound) and Clozapine may lead to a major life threatening interaction when taken with Bosutinib
Asenapine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) covaries with PTK2B (Gene) and PTK2B (Gene) is bound by Bosutinib (Compound)
Asenapine (Compound) causes Electrocardiogram QT prolonged (Side Effect) and Electrocardiogram QT prolonged (Side Effect) is caused by Famotidine (Compound) and Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib
Asenapine (Compound) causes Alanine aminotransferase increased (Side Effect) and Alanine aminotransferase increased (Side Effect) is caused by Rilpivirine (Compound) and Rilpivirine may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib
Asenapine (Compound) resembles Amoxapine (Compound) and Amoxapine (Compound) resembles Quetiapine (Compound) and Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib